PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.03%
Revenue growth at 50-75% of MRVL's 7.01%. Martin Whitman would worry about competitiveness or product relevance.
191.95%
Gross profit growth above 1.5x MRVL's 7.31%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
159.23%
EBIT growth above 1.5x MRVL's 18.77%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
159.23%
Operating income growth above 1.5x MRVL's 18.77%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
160.20%
Net income growth above 1.5x MRVL's 16.36%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
161.29%
EPS growth above 1.5x MRVL's 14.71%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
161.29%
Diluted EPS growth above 1.5x MRVL's 15.15%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.80%
Share count expansion well above MRVL's 0.27%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.73%
Slight or no buyback while MRVL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
517.80%
OCF growth above 1.5x MRVL's 15.24%. David Dodd would confirm a clear edge in underlying cash generation.
5868.30%
FCF growth above 1.5x MRVL's 15.88%. David Dodd would verify if the firm’s strategic investments yield superior returns.
191.98%
10Y revenue/share CAGR under 50% of MRVL's 1198.54%. Michael Burry would suspect a lasting competitive disadvantage.
27.81%
5Y revenue/share CAGR under 50% of MRVL's 96.60%. Michael Burry would suspect a significant competitive gap or product weakness.
-27.28%
Negative 3Y CAGR while MRVL stands at 15.03%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
722.75%
10Y OCF/share CAGR under 50% of MRVL's 4583.76%. Michael Burry would worry about a persistent underperformance in cash creation.
122.93%
Below 50% of MRVL's 287.41%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-46.34%
Negative 3Y OCF/share CAGR while MRVL stands at 1255.33%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
107.29%
Below 50% of MRVL's 6871.68%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
14.91%
Below 50% of MRVL's 139.96%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-65.38%
Negative 3Y CAGR while MRVL is 3712.53%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
449.65%
Below 50% of MRVL's 1747.03%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
89.75%
5Y equity/share CAGR 1.25-1.5x MRVL's 63.10%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
12.42%
Below 50% of MRVL's 43.75%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.90%
Our AR growth while MRVL is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-12.99%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
4.94%
Asset growth 1.25-1.5x MRVL's 4.34%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
4.15%
75-90% of MRVL's 4.64%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-1.58%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-2.90%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.29%
We cut SG&A while MRVL invests at 11.27%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.